Renal Cell Carcinoma Molecular Targets and Clinical Applications
The third edition of this critically acclaimed book has updated and expanded the survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma. Internationally renowned editors and contributors explore the la
- PDF / 7,254,318 Bytes
- 620 Pages / 439.42 x 683.15 pts Page_size
- 31 Downloads / 221 Views
Renal Cell Carcinoma
Molecular Targets and Clinical Applications Third Edition
123
Renal Cell Carcinoma
Ronald M. Bukowski • Robert A. Figlin Robert J. Motzer Editors
Renal Cell Carcinoma Molecular Targets and Clinical Applications Third Edition
Editors Ronald M. Bukowski, M.D. Taussig Cancer Center Cleveland Clinic Cleveland, OH, USA Robert J. Motzer, M.D. Department of Medicine Memorial Sloan Kettering Cancer Center New York, NY, USA
Robert A. Figlin, M.D., F.A.C.P. Director, Division of Hematology Oncology Samuel Oschin Comprehensive Cancer Institute Cedars-Sinai Medical Center Los Angeles, CA, USA
ISBN 978-1-4939-1621-4 ISBN 978-1-4939-1622-1 (eBook) DOI 10.1007/978-1-4939-1622-1 Springer New York Heidelberg Dordrecht London Library of Congress Control Number: 2014955159 © Springer Science+Business Media New York 2015 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher’s location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com)
1st Edition Preface
Renal cell carcinoma represents a heterogeneous group of tumors, the most common of which is clear cell adenocarcinoma. The annual incidence of this tumor appears to be rising and approximately 12,000 individuals die from this cancer annually in the United States. One third of patients who present have metastatic disease at the time of diagnosis, and another 40 % who unde
Data Loading...
